Press Releases

Press Releases

Stay updated on the latest Vistagen News and get the details about important events, public financial reports, and our product pipeline updates.

Dr. Monti developed the innovative scientific platform that enabled the early research and development of VistaGen's PH94B and PH10, intranasal neuroactive steroid drug candidates (pherines) with potential for the rapid-onset treatment of anxiety and depression disorders, respectively SOUTH SAN
Positive FDA Meeting Sets Key Pathway for Pivotal PH94B Phase 3 Study in the Second Quarter of 2021 Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Positive New Data from Second Preclinical Study of AV-101 in Combination with
New electrophysiological data demonstrate that PH94B does not directly modulate GABA (gamma aminobutyric acid) receptors SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety,
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that senior management will participate in the
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company received written notification
New Results Complement Earlier Positive Preclinical Data Demonstrating Increase in Brain Concentration Effects SOUTH SAN FRANCISCO, Calif., Sept. 3, 2020 /PRNewswire/ --  VistaGen Therapeutics  (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression,
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company will be presenting at the
Company Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Subsequent to Quarter-end Positive Meeting with the FDA Sets Key Aspects of Pivotal PH94B Phase 3 Study SOUTH SAN FRANCISCO, Calif., Aug.
SAN FRANCISCO, Aug. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the underwriters of its previously announced public
SOUTH SAN FRANCISCO, Calif., Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its previously announced